News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
245,272 Results
Type
Article (7231)
Company Profile (26)
Press Release (238015)
Section
Business (88291)
Career Advice (549)
Deals (15631)
Drug Delivery (12)
Drug Development (21073)
Employer Resources (32)
FDA (4011)
Job Trends (4368)
News (129258)
Policy (8280)
Tag
2024 BioCapital Digital (3)
2024 BioMidwest Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (1)
Academia (615)
Academic (1)
Adcomms (4)
Allergies (12)
Alliances (17278)
ALS (20)
Alzheimer's disease (273)
Antibody-drug conjugate (ADC) (11)
Approvals (4025)
Artificial intelligence (51)
Autoimmune disease (2)
Automation (2)
Bankruptcy (108)
Best Places to Work (3201)
BIOSECURE Act (2)
Biosimilars (11)
Biotechnology (27)
Bladder cancer (10)
Brain cancer (8)
Breast cancer (50)
Cancer (458)
Cardiovascular disease (20)
Career advice (467)
Career pathing (5)
CAR-T (33)
Cell therapy (117)
Cervical cancer (2)
Clinical research (17460)
Collaboration (207)
Compensation (146)
Complete response letters (2)
COVID-19 (516)
CRISPR (11)
C-suite (93)
Cystic fibrosis (17)
Data (528)
Decentralized trials (1)
Denatured (3)
Depression (6)
Diabetes (41)
Diagnostics (2244)
Digital health (3)
Diversity, equity & inclusion (12)
Drug discovery (26)
Drug pricing (9)
Drug shortages (1)
Duchenne muscular dystrophy (11)
Earnings (41321)
Editorial (1)
Employer branding (7)
Employer resources (32)
Events (39926)
Executive appointments (296)
FDA (4260)
Featured Employer (7)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (211)
Gene editing (19)
Generative AI (3)
Gene therapy (48)
GLP-1 (116)
Government (652)
Guidances (16)
Healthcare (5543)
Huntington's disease (1)
IgA nephropathy (2)
Immunology and inflammation (17)
Indications (6)
Infectious disease (541)
Inflammatory bowel disease (26)
Inflation Reduction Act (2)
Influenza (9)
Intellectual property (21)
Interviews (63)
IPO (8019)
IRA (4)
Job creations (1264)
Job search strategy (432)
Kidney cancer (6)
Labor market (5)
Layoffs (110)
Leadership (6)
Legal (2431)
Liver cancer (18)
Lung cancer (52)
Lymphoma (31)
Management (10)
Manufacturing (56)
MASH (26)
Medical device (4222)
Medtech (4223)
Mergers & acquisitions (7802)
Metabolic disorders (119)
Multiple sclerosis (9)
NASH (6)
Neurodegenerative disease (11)
Neuropsychiatric disorders (1)
Neuroscience (366)
NextGen: Class of 2025 (1883)
Non-profit (1040)
Northern California (891)
Now hiring (2)
Obesity (54)
Opinion (38)
Ovarian cancer (17)
Pain (14)
Pancreatic cancer (13)
Parkinson's disease (21)
Partnered (7)
Patents (30)
Patient recruitment (27)
Peanut (6)
People (26871)
Pharmaceutical (7)
Pharmacy benefit managers (1)
Phase I (5292)
Phase II (7658)
Phase III (5943)
Pipeline (492)
Podcasts (3)
Policy (11)
Postmarket research (656)
Preclinical (2161)
Press Release (70)
Prostate cancer (26)
Psychedelics (3)
Radiopharmaceuticals (106)
Rare diseases (70)
Real estate (2145)
Recruiting (9)
Regulatory (5582)
Reports (15)
Research institute (658)
Resumes & cover letters (77)
Rett syndrome (2)
Schizophrenia (20)
Series A (30)
Series B (23)
Service/supplier (1)
Sickle cell disease (8)
Southern California (692)
Special edition (1)
Spinal muscular atrophy (38)
Sponsored (3)
Startups (1219)
Stomach cancer (1)
Supply chain (12)
United States (7104)
Vaccines (72)
Venture capitalists (5)
Webinars (5)
Weight loss (20)
Women's health (5)
Date
Today (34)
Last 7 days (224)
Last 30 days (884)
Last 365 days (11140)
2025 (2590)
2024 (11912)
2023 (14243)
2022 (20052)
2021 (21285)
2020 (20051)
2019 (14692)
2018 (11378)
2017 (11330)
2016 (10430)
2015 (13514)
2014 (10677)
2013 (8693)
2012 (9105)
2011 (9696)
2010 (9404)
Location
Africa (219)
Alabama (15)
Alaska (2)
Arizona (59)
Arkansas (1)
Asia (12604)
Australia (1866)
California (1889)
Canada (711)
China (77)
Colorado (81)
Connecticut (96)
Delaware (28)
Europe (27001)
Florida (262)
Georgia (72)
Idaho (24)
Illinois (119)
India (5)
Indiana (60)
Iowa (1)
Japan (64)
Kansas (27)
Kentucky (10)
Louisiana (5)
Maine (39)
Maryland (232)
Massachusetts (1528)
Michigan (89)
Minnesota (155)
Mississippi (1)
Missouri (31)
Montana (16)
Nebraska (12)
Nevada (22)
New Hampshire (16)
New Jersey (569)
New Mexico (6)
New York (499)
North Carolina (331)
North Dakota (3)
Northern California (891)
Ohio (66)
Oklahoma (5)
Oregon (4)
Pennsylvania (361)
Rhode Island (18)
South America (318)
South Carolina (5)
Southern California (692)
Tennessee (38)
Texas (234)
Utah (57)
Virginia (47)
Washington D.C. (11)
Washington State (164)
West Virginia (2)
Wisconsin (21)
245,272 Results for "talis biomedical corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Bleichmar Fonti & Auld LLP Announces a Proposed Settlement in the In re Talis Biomedical Corporation Securities Litigation
December 23, 2024
·
4 min read
Biotech Bay
Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
Talis Biomedical Corporation announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value.
November 14, 2023
·
7 min read
Press Releases
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025
March 31, 2025
·
12 min read
Business
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
Talis Biomedical Corporation today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023.
August 2, 2023
·
5 min read
Business
Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update
Talis Biomedical Corporation, a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, reported financial results for the second quarter ended June 30, 2023, and provided a business update.
August 10, 2023
·
8 min read
Deals
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
Talis Biomedical Corporation today announced that it received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated July 20, 2023, that the Company has regained compliance with the minimum bid price requirement of at least $1.00 per share.
July 24, 2023
·
3 min read
Business
Talis Biomedical Announces Business Update and First Quarter 2023 Financial Results
Talis Biomedical Corporation announced a business update and reported financial results for the first quarter ended March 31, 2023.
May 11, 2023
·
7 min read
Biotech Bay
New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu
Talis Biomedical Corporation (Nasdaq: TLIS) today announced new data supporting the development of its planned CT/NG/TV and vaginal infection panels.
July 27, 2023
·
8 min read
Deals
Talis Biomedical Announces 1-for-15 Reverse Stock Split
Talis Biomedical Corporation today announced that it will effect a 1-for-15 reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share (the “Reverse Stock Split”), effective at 5:00 p.m. Eastern time on July 5, 2023 (the “Effective Time”).
July 5, 2023
·
5 min read
Press Releases
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 28, 2025
·
11 min read
1 of 24,528
Next
